BBVA USA’s West Pharmaceutical WST Stock Holding History

BBVA USA’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$42K	Sell	98 -6	-6%	-$2.53K	﹤0.01%	683
2021 Q2	$37K	Buy	+104	New	+$34.4K	﹤0.01%	717

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBVA USA's WST Position: Q3 2021 in Review

BBVA USA reduced its West Pharmaceutical (WST) stake by 5.8% in Q3 2021, selling an estimated $2.53K and leaving 98 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #683.

BBVA USA first reported a position in WST in Q2 2021 and has held it in 2 quarters since. 669 funds tracked by Wall St. Rank hold WST as of Q3 2021.

BBVA USA held 98 shares of West Pharmaceutical worth $42K as of Q3 2021.
BBVA USA sold 6 West Pharmaceutical shares in Q3 2021, an estimated $2.53K.
West Pharmaceutical made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #683 holding.
BBVA USA first reported a position in West Pharmaceutical in Q2 2021 and has held it in 2 quarters since.
669 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.